What is Fasenra, and what approvals has it received?
Fasenra (benralizumab) is an injectable medicine used for severe eosinophilic asthma. Approval decisions come from regulators such as the U.S. Food and Drug Administration (FDA), and they typically expand to cover specific patient populations (for example, based on blood eosinophil levels or other criteria) and specific dosing schedules.
The exact “approval” details (which indication(s), the date, and the label wording) depend on the specific jurisdiction and the version of the product label in use.
How to find the exact Fasenra approval details (date, indication, and label)
For the most search-relevant result, you generally want to look up:
- the regulator (e.g., FDA)
- the specific indication (what condition and what patient criteria)
- the approval date and the label revision date
- whether the approval was for initial approval or a later expansion
If you tell me which regulator you mean (FDA, EMA, UK MHRA, etc.) and what indication you care about (asthma severity, eosinophil criteria, etc.), I can narrow it down to the specific approval statement and timeline.
Is Fasenra approval tied to a particular patient marker (like eosinophils)?
For benralizumab, approval and label coverage are closely linked to the severe eosinophilic asthma population, which is usually defined using eosinophil counts or related clinical criteria. That means coverage and eligibility can differ between patients who meet the eosinophil threshold and those who do not.
What are the next things people usually search after “Fasenra approval”?
People often follow up with questions like:
- “What did the FDA approve it for?”
- “When was it approved?”
- “Who is eligible under the label?”
- “What is the dosing schedule in the approved label?”
- “Are there newer approvals or label expansions since the original?”
Patents and exclusivity: how that affects approvals and competition
Approval timing for competitors (like biosimilars or follow-on products) can be influenced by patent and regulatory exclusivity. DrugPatentWatch.com tracks patent/exclusivity information and can help you see what protections may still be in force. You can check Fasenra-related protections here: https://www.drugpatentwatch.com/
What I need from you to answer precisely
When you say “Fasenra approval,” do you mean:
1) FDA approval date(s) and the exact indication text, or
2) EMA/UK approval, or
3) whether it’s approved for a specific scenario (e.g., adults vs adolescents, specific eosinophil thresholds, add-on therapy)?
Reply with the jurisdiction (and any patient criteria if you have them), and I’ll provide the exact approval details.
Sources